Deciphex, an innovator in Pathology AI, announces the strategic appointment of Dr. Pierre Moulin as Chief Scientific Officer. Dr Moulin, MD, PhD, MBA has established himself as a distinguished physician-scientist and pathologist, with specialist interest in the realms of data science and artificial intelligence in pathology.
Pierre has previously held senior research positions in 2 of the top 10 pharmaceutical companies, has been a key initiator of the IMI BigPicture project along with serving as an attending pathologist and lecturer at CHUV and the University of Basel. As part of his experience, He has previously led the development of a pathology unit focused on adverse event mechanisms and made substantial contributions to enhancing clinical trials through his unique integration of molecular profiling, digital pathology, image analysis, and artificial intelligence; improving their efficiency and precision. As a key initiator of the BigPicture project, Dr. Moulin has managed large-scale, collaborative initiatives, bringing together various experts to advance better access to pathology data for AI researchers.
In his statement, Dr. Moulin expressed enthusiasm about joining Deciphex, emphasizing the opportunity to use AI in pathology to transform diagnostics and patient care.
“I have long admired Deciphex’s work at the forefront of pathology AI and am consistently impressed by their outstanding collection of talent. We share a common vision, one that aims at driving the future of pathology by incorporating AI in both clinical practice and clinical trials. It’s an honor to be a part of this endeavor,” said Dr. Moulin.
Dr. Donal O’Shea, CEO of Deciphex, highlighted the significance of Dr. Moulin’s appointment:
“Bringing Dr. Moulin on board is a strategic move that strengthens our commitment to being leaders in Pathology AI. His extensive experience and innovative approach in digital pathology are aligned with our goals to enhance clinical trial methodologies and improve patient outcomes.”
Dr. Moulin’s appointment is a testament to Deciphex’s dedication to advancing digital pathology. His leadership is expected to accelerate the company’s AI research and development program, and expand its impact in supporting clinical trials.
Deciphex is a pioneering leader in digital pathology, committed to addressing the growing global demand in pathology, and integrate AI driving efficient, high-quality reporting, enhancing patient care, and accelerating drug development. With a diverse and experienced team and cutting-edge platforms like Diagnexia and Patholytix, Deciphex is set to redefine the future of pathology.
FOR MEDIA INQUIRIES OR FURTHER INFORMATION, PLEASE CONTACT:
Commercial Marketing Director